

Supplementary Table 2. Baseline characteristics of the patients treated with surgical therapies (n=1,053)

Variable	Surgical resection (n=998, 16.7%)	Liver transplantation (n=55, 0.9%)
Demographic variable		
Age (years)	56.0 (49.0-64.0)	52.0 (47.0-58.5)
Sex (male)	792 (79.4)	45 (81.8)
Diabetes	196 (19.6)	8 (14.5)
Hypertension	312 (31.7)	5 (9.3)
Body mass index (kg/m ²)	23.7 (21.9-25.8)	24.8 (22.4-27.4)
Smoking	428 (43.4)	25 (46.3)
Etiology	n=879	n=52
HBV [*]	710 (80.8)	46 (88.5)
HCV	64 (7.3)	4 (7.7)
Alcohol	87 (9.9)	2 (3.8)
Others	18 (2.0)	0
Performance status [†]	n=782	n=41
0	705 (90.2)	30 (73.2)
1	72 (9.2)	6 (14.6)
2	4 (0.5)	3 (7.3)
3	1 (0.1)	0
4	0	2 (4.9)
Ascites	n=998	n=55
None	957 (95.9)	37 (67.3)
Mild	37 (3.7)	9 (16.4)
Moderate to severe	4 (0.4)	9 (16.4)
Encephalopathy	n=991	n=55
None	988 (99.7)	51 (92.7)
Mild to moderate (grade 1 or 2)	2 (0.2)	4 (7.3)
Severe (grade 3 or 4)	1 (0.1)	0
Laboratory variable		
Total bilirubin (mg/dL)	0.8 (0.6-1.0)	1.5 (0.9-2.9)
Serum albumin (g/dL)	4.2 (3.8-4.4)	3.1 (2.8-3.6)
Alanine aminotransferase (IU/L)	33.0 (22.0-48.0)	33.0 (26.0-42.0)
Platelet count (10 ⁹ /L)	163.0 (124.0-208.0)	74.0 (53.0-112.0)
Prothrombin time (INR)	1.05 (1.00-1.11)	1.31 (1.15-1.54)
Creatinine (mg/dL)	0.90 (0.80-1.00)	0.90 (0.76-1.00)
Sodium (mmol/L)	140.0 (138.0-142.0)	138.0 (135.0-140.5)
Glucose (mg/dL)	105.0 (93.5-127.0)	104.0 (90.0-133.5)
Total Cholesterol (mg/dL)	164.0 (142.0-185.0)	140.0 (116.0-159.0)
Alpha-fetoprotein (ng/mL)	28.3 (5.4-304.3)	17.2 (6.5-106.4)
PIVKA-II (mAU/mL)	79.5 (29.0-500.0)	31.5 (16.0-194.0)

Supplementary Table 2. Continued

Variable	Surgical resection (n=998, 16.7%)	Liver transplantation (n=55, 0.9%)
Child-Turcotte-Pugh class	n=963	n=52
A	919 (95.4)	24 (46.2)
B	43 (4.5)	20 (38.5)
C	1 (0.1)	8 (15.4)
MELD score	7.4 (6.8-8.6)	11.2 (8.4-15.4)
MELD-Na score	8.1 (7.1-9.8)	14.1 (9.6-19.2)
Tumor variable		
Tumor number	n=988	n=53
1	849 (85.9)	26 (49.1)
2	112 (11.3)	11 (20.8)
3	13 (1.3)	4 (7.5)
4	3 (0.3)	1 (1.9)
≥5	11 (1.1)	11 (20.8)
Maximal tumor diameter (cm)	3.2 (2.2-5.0)	2.5 (1.5-4.0)
Portal vein invasion	60 (6.0)	7 (12.7)
Hepatic vein invasion	14 (1.4)	0
Bile duct invasion	14 (1.4)	0
Lymph node metastasis	14 (1.4)	0
Distant metastasis	14 (1.4)	0
Modified UICC stage	n=988	n=53
Stage I	120 (12.1)	6 (11.3)
Stage II	674 (68.2)	23 (43.4)
Stage III	155 (15.7)	22 (41.5)
Stage IV-A	25 (2.5)	2 (3.8)
Stage IV-B	14 (1.4)	0
BCLC stage	n=956	n=51
0	89 (9.3)	2 (3.9)
A	646 (67.6)	17 (33.3)
B	66 (6.9)	13 (25.5)
C	153 (16.0)	10 (19.6)
D	2 (0.2)	9 (17.6)

Values are expressed as median (interquartile range) or number (%).

HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PIVKA-II, protein induced by vitamin K absence-II; MELD, Model for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.

*Patients co-infected with HBV and HCV were also included; †Performance status was defined as follows: 0, fully active without symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the time and incapable of self-care.